'Inspired' by Ipsen's mission, Sandra Silvestri joins as next CMO; Exicure's slide continues with CEO, CFO exits
Ipsen is waiting on an FDA decision this summer for what could be the first drug to treat an ultra-rare bone disease called fibrodysplasia ossificans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
